Kura Oncology, Inc. (KURA)
13.25
+0.10
(+0.76%)
USD |
NASDAQ |
Sep 04, 16:00
13.26
+0.01
(+0.08%)
After-Hours: 20:00
Kura Oncology Research and Development Expense (Quarterly) : 61.89M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 61.89M |
| March 31, 2026 | 65.26M |
| December 31, 2025 | 64.41M |
| September 30, 2025 | 67.91M |
| June 30, 2025 | 62.78M |
| March 31, 2025 | 55.97M |
| December 31, 2024 | 52.27M |
| September 30, 2024 | 41.70M |
| June 30, 2024 | 39.73M |
| March 31, 2024 | 36.27M |
| December 31, 2023 | 32.53M |
| September 30, 2023 | 29.33M |
| June 30, 2023 | 28.18M |
| March 31, 2023 | 25.19M |
| December 31, 2022 | 22.67M |
| September 30, 2022 | 24.97M |
| June 30, 2022 | 24.26M |
| March 31, 2022 | 20.91M |
| December 31, 2021 | 20.96M |
| September 30, 2021 | 22.37M |
| June 30, 2021 | 21.07M |
| March 31, 2021 | 20.32M |
| December 31, 2020 | 17.52M |
| Date | Value |
|---|---|
| September 30, 2020 | 16.60M |
| June 30, 2020 | 13.70M |
| March 31, 2020 | 12.58M |
| December 31, 2019 | 13.46M |
| September 30, 2019 | 12.54M |
| June 30, 2019 | 11.44M |
| March 31, 2019 | 10.38M |
| December 31, 2018 | 12.08M |
| September 30, 2018 | 11.66M |
| June 30, 2018 | 11.48M |
| March 31, 2018 | 11.57M |
| December 31, 2017 | 8.119M |
| September 30, 2017 | 7.142M |
| June 30, 2017 | 5.652M |
| March 31, 2017 | 5.513M |
| December 31, 2016 | 5.503M |
| September 30, 2016 | 5.316M |
| June 30, 2016 | 4.936M |
| March 31, 2016 | 4.649M |
| December 31, 2015 | 5.113M |
| September 30, 2015 | 4.674M |
| June 30, 2015 | 4.191M |
| March 31, 2015 | 3.628M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 10.50M |
| Fortress Biotech, Inc. | 0.805M |
| Syndax Pharmaceuticals, Inc. | 68.03M |
| Spero Therapeutics, Inc. | 3.434M |
| Gossamer Bio, Inc. | 26.41M |